Organization
MorphoSys AG
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
MorphoSys AG
... Additional ADSs, Leading to Total Gross Proceeds of USD 239 million DGAP-News: MorphoSys AG / Key word(s): Corporate Action/IPO MorphoSys Announces Closing of Nasdaq IPO ...
... Act] with the objective of Europe-wide distribution DGAP Total Voting Rights Announcement: MorphoSys AG / Total Voting Rights Announcement MorphoSys AG: Release according to Article ...
... MorphoSys has supersized its IPO, pulling in $208 million to develop its anti-CD19 ...
... 300,000 American Depositary Shares (ADS) in the United States DGAP-Ad-hoc: MorphoSys AG / Key word(s): Corporate Action MorphoSys Resolves a Capital Increase to ...
... (ADS) Offering in the United States DGAP-Ad-hoc: MorphoSys AG / Key word(s): Corporate Action/IPO Ad hoc: MorphoSys Announces Launch of ...
... Treatment of Moderate-to-Severe Plaque Psoriasis in Brazil and Australia DGAP-News: MorphoSys AG / Key word(s): Regulatory Approval MorphoSys Announces Approvals for Tremfya(R) (Guselkumab) ...
... took a little of the shine off its upcoming takeover by Sanofi. MorphoSys filed to raise $150 million in a Nasdaq IPO. Redx halted an ...
... MorphoSys has filed to raise $150 million in a Nasdaq IPO. The listing ...
... for a Proposed American Depositary Shares (ADS) Offering DGAP-Ad-hoc: MorphoSys AG / Key word(s): Corporate Action Ad hoc: MorphoSys Files Registration Statement ...
... MorphoSys is hoping to hustle MOR208 through an early, speedy regulatory filing after ...
... Heptares, which has fallen foul of new CEO Kåre Schultz’s R&D rejig. MorphoSys raised the prospect of a quickie approval of MOR208 after posting midphase ...
... DGAP-News: MorphoSys AG / Key word(s): Final Results Conference call and webcast (in English) ...
... Lenalidomide in Aggressive Lymphoma (r/r DLBCL) DGAP-News: MorphoSys AG / Key word(s): Study MorphoSys Reports Updated Data from L-MIND Study ...
... Group Pty Ltd, Jaybro, Mãe Terra Produtos Naturais Ltda., McDermott International, Inc., MorphoSys AG, Morris Corporation Group Pty Ltd, Natural Resource Partners, L.P., Palatin Technologies, ...
... 2014-2017. Before his time at Lanthio, Dr. Schwer was Senior Director at MorphoSys AG from 2010 until 2014. In this period, he served as strategic ...
... at Upcoming Investor Conferences / Key word(s): Conference MorphoSys AG MorphoSys AG MorphoSys AG . The www.morphosys.com/conference-calls. MorphoSys AG J.P. Morgan Annual Healthcare Conference Date: ...
... Aggressive Lymphoma (R/R DLBCL) at ASH 2017 Conference DGAP-News: MorphoSys AG / Key word(s): Study results/Conference MorphoSys Presents Clinical Data on MOR208 ...
... Tremfya(R) (Guselkumab) for the Treatment of Moderate-to-Severe Plaque Psoriasis in Canada DGAP-News: MorphoSys AG / Key word(s): Regulatory Approval MorphoSys Announces That Its Licensee Janssen ...
... MorphoSys has found a buyer for the Chinese rights to multiple myeloma candidate ...
... brought Synpromics on board to help its Parkinson’s gene therapy research program. MorphoSys offloaded the Chinese rights to multiple myeloma asset MOR202 to I-Mab Biopharma. ...
... DGAP-News: MorphoSys AG / Key word(s): Change in Forecast/Agreement The issuer is solely responsible ...
... Tremfya(R) (Guselkumab) in Europe for the Treatment of Moderate-to-Severe Plaque Psoriasis DGAP-News: MorphoSys AG / Key word(s): Regulatory Approval MorphoSys Announces That Its Licensee Janssen ...
... DGAP-News: MorphoSys AG / Key word(s): Quarterly / Interim Statement Conference call and webcast ...
... What about recently approved products, such as Siliq/Kyntheum (brodalumab), and Tremfya (guselkumab; Janssen/MorphoSys)? Clinical and commercial differentiation will become critical and as the treatment landscape ...
Subscribe now for full coverage on MorphoSys AG
Start My Free Trial